Direct thrombin inhibitors and factor Xa inhibitors for atrial fibrillation

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 10, 2017, Pages

  Mahtani, Kamal R ^a   Heneghan, Carl J ^a   Tai, Tracy W ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; PRIORITY JOURNAL; RETRACTED ARTICLE;

EID: 85032894217     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009787.pub2     Document Type: Article

References (34)

1. Agarwal A, York M, Kantharia BK, Ezekowitz M. Atrial fibrillation: Modern concepts and management. Annual Review of Medicine 2005; Vol. 56:475-94.
2. Aguilar Maria I, Hart R, Pearce Lesly A. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD006186.pub2; CD006186]
3. Albers GW, Diener H-C, Frison L, Grind M, Nevinson M, Partridge S, et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005; Vol. 293, issue 6:690-8.
4. Amadeus I, Bousser MG, Bouthier J, Buller HR, Cohen AT, Crijns H, et al. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial.[Erratum appears in Lancet. 2008 Dec 13;372(9655):2022. Note: Thorp-Pedersen, C [corrected to Torp-Pedersen, C]]. Lancet 2008; Vol. 371, issue 9609:315-21.
5. Astellas Pharma I. Direct factor Xa inhibitor YM150 for prevention of stroke in subjects with non-valvular atrial fibrillation. ClinicalTrials.gov 2007.
6. Brieger DB, Freedman SB. Delirium cordis: can we predict the onset of atrial fibrillation?. Lancet. 2009/03/03 2009; Vol. 373, issue 9665:698-700. [1474-547X: (Electronic)]
7. Bruins Slot Karsten MH, Berge E. Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation. Cochrane Database of Systematic Reviews 2011, Issue 2. [DOI: 10.1002/14651858.CD008980; CD008980]
8. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009/09/01 2009; Vol. 361, issue 12:1139-51. [1533-4406: (Electronic)]
9. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011/02/12 2011; Vol. 364, issue 9:806-17. [1533-4406: (Electronic)]
10. Eriksson BI, Quinlan DJ, Eikelboom JW. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. Annual Review of Medicine 2011; Vol. 62:41-57.
11. Flaker GC, Gruber M, Connolly SJ, Goldman S, Chaparro S, Vahanian A, et al. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. American Heart Journal 2006; Vol. 152, issue 5:967-73.
12. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011/08/30 2011; Vol. 365, issue 11:981-92. [1533-4406: (Electronic)]
13. Hart RG, Halperin JL. Atrial fibrillation and stroke: concepts and controversies. Stroke. 2001/03/10 2001; Vol. 32, issue 3:803-8. [1524-4628: (Electronic)]
14. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007/06/20 2007; Vol. 146, issue 12:857-67. [1539-3704: (Electronic)]
15. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
16. Hirsh J, O'Donnell M, Weitz JI. New anticoagulants. Blood 2005; Vol. 105, issue 2:453-63.
17. Hughes M, Lip GY. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost. 2008/02/19 2008; Vol. 99, issue 2:295-304. [0340-6245: (Print)]
18. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003/09/12 2003; Vol. 349, issue 11:1019-26. [1533-4406: (Electronic)]
19. Investigators RAS. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. American Heart Journal 2010; Vol. 159, issue 3:340-347.e1.
20. Kaul S, Diamond GA, Weintraub WS. Trials and tribulations of non-inferiority: the ximelagatran experience. J Am Coll Cardiol. 2005/12/06 2005; Vol. 46, issue 11:1986-95. [1558-3597: (Electronic)]
21. Lafuente-Lafuente C, Mahe I, Extramiana F. Management of atrial fibrillation. Bmj. 2009/12/25 2009; Vol. 339:b5216. [1468-5833: (Electronic)]
22. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011.
23. Lip GY, Rudolf M. The new NICE guideline on atrial fibrillation management. Heart. 2006/09/06 2007; Vol. 93, issue 1:23. [1468-201X: (Electronic)]
24. Lip GY, Rasmussen LH, Olsson SB, Jensen EC, Persson AL, Eriksson U, et al. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists. Eur Heart J. 2009/08/20 2009; Vol. 30, issue 23:2897-907. [1522-9645: (Electronic)]
25. Mehta PA, Grocott-Mason R, Dubrey SW. Adherence to anticoagulation guidelines for atrial fibrillation: A district general hospital survey. British Journal of Cardiology 2004; Vol. 11, issue 6:474-7.
26. Olsson SB, Executive Steering Committee of the SIIII. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003; Vol. 362, issue 9397:1691-8.
27. Patel R, Medow M. Cost-effectiveness based pricing for dabigatran for the primary prophylaxis of stroke in elderly patients with atrial fibrillation. Journal of General Internal Medicine 2010; Vol. Conference: 33rd Annual Meeting of the Society of General Internal Medicine Minneapolis, MN United States. Conference Start: 20100428 Conference End: 20100501. Conference Publication: (var.pagings). 25:S249.
28. Schulman S, Wahlander K, Lundstrom T, Clason SB, Eriksson H. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med. 2003/10/31 2003; Vol. 349, issue 18:1713-21. [1533-4406: (Electronic)]
29. Segal JB, McNamara RL, Miller MR, Powe NR, Goodman SN, Robinson KA, et al. Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter. Cochrane Database Syst Rev. 2001/11/10 2001, issue 1:CD001938. [1469-493X: (Electronic)]
30. Taylor FC, Cohen H, Ebrahim S. Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation. BMJ (Clinical research ed.) 2001;322(7282):321-6. [PUBMED: 11159653]
31. Testai FD, Gorelick PB. New approaches to stroke prevention in atrial fibrillation. Current Treatment Options in Cardiovascular Medicine 2010; Vol. 12, issue 3:261-73.
32. Verheugt FWA. Novel oral anticoagulants to prevent stroke in atrial fibrillation. Nature Reviews Cardiology 2010; Vol. 7, issue 3:149-54.
33. Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet. 2009/01/13 2009; Vol. 373, issue 9658:155-66. [1474-547X: (Electronic)]
34. Wyndham CR. Atrial fibrillation: the most common arrhythmia. Tex Heart Inst J. 2000/11/28 2000; Vol. 27, issue 3:257-67. [0730-2347: (Print)]